CLINICAL TRIALS PROFILE FOR ETRETINATE
✉ Email this page to a colleague
All Clinical Trials for etretinate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002143 ↗ | Treatment of Psoriasis Using Acitretin in HIV-Positive Patients | Completed | Hoffmann-La Roche | Phase 3 | 1969-12-31 | To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients. |
NCT00038376 ↗ | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | Completed | M.D. Anderson Cancer Center | Phase 2 | 1990-05-08 | The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane). |
NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for etretinate
Condition Name
Clinical Trial Locations for etretinate
Trials by Country
Clinical Trial Progress for etretinate
Clinical Trial Phase
Clinical Trial Sponsors for etretinate
Sponsor Name